Cutaneous T-cell lymphoma is a cancer of the immune system that primarily affects the skin. While rare, CTCL can be aggressive, difficult to treat, and is generally not curable. The two most common subtypes are: Mycosis fungoides; Sezary syndrome.

Email Us (561) 516-5168

Dupixent Lawsuits

Q: Why is Dupixent Linked to CTCL?

Concerns about Dupixent and CTCL have been mounting: In early 2024, the FDA identified CTCL as a 'potential signal of a serious risk' associated with Dupixent and announced that it was evaluating whether regulatory action is needed. Scientific studies report that Dupixent patients may face a significantly higher risk of developing CTCL. Experts warn that Dupixent may mask early signs of CTCL or accelerate the disease, delaying diagnosis and treatment. Because CTCL often mimics eczema, many patients and doctors initially believe the drug is treating a flare-up—while the cancer continues to advance.

Dupixent Litigation | Rafferty Domnick Cunningham Yaffa

At Rafferty Domnick Cunningham & Yaffa, we represent individuals who developed Cutaneous T-cell lymphoma (CTCL) after being prescribed Dupixent (dupilumab). Patients trusted that this medication would improve their health, but instead, some are now facing a rare and aggressive cancer diagnosis. If you or a loved one was prescribed Dupixent and later developed CTCL, you may be entitled to compensation.

Our attorneys are actively investigating claims against Sanofi and Regeneron, the manufacturers of Dupixent, for failing to adequately warn doctors and patients of this life-threatening risk. Contact us today for a confidential case review.

What is Dupixent?

Dupixent is an injectable biologic medication approved by the FDA in 2017. It has been widely prescribed for multiple inflammatory conditions, including:

Atopic dermatitis (eczema)
Asthma
Chronic obstructive pulmonary disease (COPD)
Bullous pemphigoid
Other allergic or inflammatory conditions

Marketed as a breakthrough therapy, Dupixent quickly became a blockbuster drug for Sanofi and Regeneron. However, emerging evidence shows that Dupixent use may be linked to an increased risk of cutaneous T-cell lymphoma (CTCL)—a rare and aggressive form of non-Hodgkin lymphoma.

Dupixent & Cutaneous T-Cell Lymphoma (CTCL)

What is CTCL?

Cutaneous T-cell lymphoma is a cancer of the immune system that primarily affects the skin. CTCL is rare and it varies a great deal. Early-stage mycosis fungoides is often slow-moving and managed for years; advanced disease and Sézary syndrome are aggressive and difficult to treat. Mycosis fungoides is the most common form by far, accounting for roughly 57% of cases. Sézary syndrome is much rarer, under 2%, and more aggressive. The two forms named in these lawsuits are:

Mycosis fungoides
Sézary syndrome

Symptoms of CTCL

Because CTCL often resembles eczema or other skin conditions, it is frequently misdiagnosed in the early stages. Common symptoms include:

Persistent skin rashes or lesions
Patches or plaques that resemble eczema or psoriasis
Severe itching or burning skin
Enlarged lymph nodes
Redness or swelling across large areas of the body

Why is Dupixent Linked to CTCL?

Concerns about Dupixent and CTCL have been mounting:

In its October–December 2024 quarterly adverse-event report, posted at the end of March 2025, the FDA listed CTCL as a “potential signal of a serious risk” associated with Dupixent and said it was evaluating the need for regulatory action. That entry has not been updated since. The FDA has not added a lymphoma or malignancy warning to the Dupixent label, and the drug has not been recalled.
Several studies report that Dupixent patients may face a significantly higher risk of developing CTCL. Other large studies have found no increased risk, and note that atopic dermatitis itself carries an elevated lymphoma risk. The science is genuinely contested, and no one has settled it.
Experts warn that Dupixent may mask early signs of CTCL or accelerate the disease, delaying diagnosis and treatment.
Because CTCL often mimics eczema, many patients and doctors initially believe the drug is treating a flare-up—while the cancer continues to advance.

Legal Allegations Against Sanofi & Regeneron

Lawsuits against the manufacturers allege that they:

Failed to warn patients and doctors about the increased risk of CTCL.
Neglected to study Dupixent’s long-term cancer risks despite widespread use.
Marketed Dupixent aggressively as safe while ignoring emerging safety signals.
Delayed proper diagnosis and treatment by failing to disclose that Dupixent could mask or worsen CTCL symptoms.

Litigation status — updated August 8, 2026. On June 4, 2026, the U.S. Judicial Panel on Multidistrict Litigation consolidated the federal Dupixent cases into In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, in the District of New Jersey before Judge Zahid N. Quraishi. Fifteen cases across twelve federal districts were before the Panel and fourteen were transferred in, with seven more identified as likely to follow. The named defendants are Regeneron Pharmaceuticals, Sanofi-Aventis U.S. LLC, and Genzyme Corporation. No leadership appointments, bellwether trial schedule, or settlement has been announced.

Consolidation is a case-management decision that a group of lawsuits raises overlapping questions. It is not a finding that the drug causes cancer.

Who Qualifies for a Dupixent Lawsuit?

You may qualify for a Dupixent lawsuit if:

You were prescribed Dupixent (dupilumab) for eczema, asthma, COPD, bullous pemphigoid, or related conditions.
You were later diagnosed with Cutaneous T-cell lymphoma (CTCL), specifically:
- Mycosis fungoides, or
- Sézary syndrome

What Compensation May Be Available?

If you or a loved one developed CTCL after taking Dupixent, you may be entitled to compensation for:

Medical Costs
- Cancer treatments, hospitalizations, medications, and long-term care.
Lost Wages & Earning Capacity
- Compensation for missed work or inability to continue employment.
Pain and Suffering
- Damages for the physical pain, emotional trauma, and reduced quality of life.
Wrongful Death Claims
- Families of patients who passed away from Dupixent-related CTCL may be eligible for compensation.
Punitive Damages
- Where the evidence supports it, punitive damages may be sought against the manufacturers. Whether they are awarded is for a court to decide.

Why Choose Rafferty Domnick Cunningham & Yaffa?

Our firm is nationally recognized for taking on the most powerful corporations in high-stakes litigation. We have secured leadership roles in some of the country’s largest pharmaceutical and mass tort cases.

Free consultation – No cost to discuss your case.
National reach – We represent clients across the U.S. in dangerous drug cases.
Compassionate representation – We understand the life-altering impact of a CTCL diagnosis and fight tirelessly for patients and families.
Trial-ready lawyers – at RDCY, we are experienced trial lawyers. If Sanofi and Regeneron refuse accountability, we are prepared to take cases to trial.